Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.
Cappelletto A; Alfì E; Volf N; Vu TVA; Bortolotti F; Ciucci G; Vodret S; Fantuz M; Perin M; Colliva A; Rozzi G; Rossi M; Ruozi G; Zentilin L; Vuerich R; Borin D; Lapasin R; Piazza S; Chiesa M; Lorizio D; Triboli L; Kumar S; Morello G; Tripodo C; Pinamonti M; Piperno GM; Benvenuti F; Rustighi A; Jo H; Piccolo S; Del Sal G; Carrer A; Giacca M; Zacchigna S.
J Exp Clin Cancer Res
(Unknown)
Published: 2024
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast…
Santana-Hernández S; Suarez-Olmos J; Servitja S; Berenguer-Molins P; Costa-Garcia M; Comerma L; Rea A; Perera-Bel J; Menendez S; Arpí O; Bermejo B; Martínez MT; Cejalvo JM; Comino-Méndez I; Pascual J; Alba E; López-Botet M; Rojo F; Rovira A; Albanell J; Muntasell A.
J Exp Clin Cancer Res
(Unknown)
Published: 2024
ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan…
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ.
J Exp Clin Cancer Res
(Unknown)
Published: 2024
Immune checkpoints are predominantly co-expressed by clonally expanded CD4<sup>+</sup>FoxP3<sup>+</sup> intratumoral T-…
Bredel D; Tihic E; Mouraud S; Danlos FX; Susini S; Aglave M; Alfaro A; Mohamed-Djalim C; Rouanne M; Halse H; Bigorgne A; Tselikas L; Dalle S; Hartl DM; Baudin E; Guettier C; Vibert E; Rosmorduc O; Robert C; Ferlicot S; Parier B; Albiges L; de Montpreville VT; Besse B; Mercier O; Even C; Breuskin I; Classe M; Radulescu C; Lebret T; Pautier P; Gouy S; Scoazec JY; Zitvogel L; Marabelle A; Bonvalet M.
J Exp Clin Cancer Res
(Unknown)
Published: 2023